Results 31 to 40 of about 3,125,328 (279)

Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]

Research in Oncology, 2021
Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei, Eman Dessouky, Thanaa I. Shalaby, Sarah K. Amer, Rasha Nassra   +4 more
doaj   +1 more source

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner

Biomedicines, 2022
Treatment of pancreatic ductal adenocarcinoma (PDAC), a dismal disease with poor survival rates, is hampered by the high prevalence of chemotherapy resistance.
C. Arnold Spek, Hella L. Aberson, JanWillem Duitman   +2 more
doaj   +1 more source

GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer [PDF]

PeerJ, 2022
Background Pancreatic ductal adenocarcinoma (PDAC) has the worst five-year overall survival rate among all cancer types. Acquired chemoresistance is considered one of the main reasons for this dismal prognosis, and the mechanism of chemoresistance is ...
Chen Chen, Binfeng Wu, Mingge Wang, Jinghua Chen, Zhaohui Huang, Jin-Song Shi   +5 more
doaj   +2 more sources

Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance

Journal of experimental & clinical cancer research : CR, 2023
Background Gemcitabine resistance (GR) is a significant clinical challenge in pancreatic adenocarcinoma (PAAD) treatment. Macrophages in the tumor immune-microenvironment are closely related to GR.
Shengwei Jiang, Tingwei Deng, Huan Cheng, Weihan Liu, D. Shi, Jiahui Yuan, Zhiwei He, Weiwei Wang, Boning Chen, Li Ma, Xianbin Zhang, P. Gong   +11 more
semanticscholar   +1 more source

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1

Molecular Oncology, 2022
Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of gemcitabine
Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino   +12 more
doaj   +1 more source

hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma

Molecular Cancer, 2023
Background Circular RNAs (circRNAs) play important roles in the occurrence and development of cancer and chemoresistance. DNA damage repair contributes to the proliferation of cancer cells and resistance to chemotherapy-induced apoptosis.
Lei Xu, Xiao Ma, Xiu-zhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo, Mengmeng Zhao, Zeqiang Ren, Pengbo Zhang   +12 more
semanticscholar   +1 more source

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer

Cells, 2023
Pancreatic cancer is characterized by a poor prognosis, with its five-year survival rate lower than that of any other cancer type. Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of ...
Myeong Jin Kim, Hyung Sun Kim, H. Kang, D. Lee, Woosol Chris Hong, J. Kim, Minsoo Kim, Jae-Ho Cheong, Hyo Jung Kim, Joon Seong Park   +9 more
semanticscholar   +1 more source

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Journal of Pharmacological Sciences, 2015
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo   +16 more
doaj   +1 more source

PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer

Experimental and Molecular Medicine, 2020
Pancreatic cancer: Exploring a pathway to drug resistance A cell membrane protein called PROM2 promotes the resistance of pancreatic cancer to the anti-cancer drug gemcitabine, suggesting PROM2 and the molecular signaling pathway it stimulates could be ...
Wenbin Li, Yue Zhu, Kelin Zhang, Xianhuan Yu, Haoming Lin, Wenrui Wu, Yaorong Peng, Jian Sun   +7 more
doaj   +1 more source

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]

PLoS ONE, 2016
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu, Chen Lin, Ming-Ming Liu, Jian Zhang, Zhong-Hua Tao, Xi-Chun Hu   +5 more
doaj   +1 more source